North America Autoimmune Disease Therapeutics Market (2019-2025)
The North America Autoimmune Disease Therapeutics Market would witness market growth of 3.72% CAGR during the forecast period (2019–2025).
Approximately 50 million Americans suffer from autoimmune diseases, according to the National Institute of Health. The diseases are estimated to be one of the top 10 causes of death in females under the age of 65 and are the second largest cause of chronic disease. It is also the top cause of morbidity in females in the U.S. There are more than 80 clinically distinct types of autoimmune diseases recognized to date. Some of the prevalent kinds of autoimmune diseases are Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel illness, and due to the increasing autoimmune disease incidence, the demand for drugs used in autoimmune disease treatment is also increasing.
Based on Indication, the market is segmented into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications. Based on Drug Class, the market is segmented into Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs (Nonsteroidal anti-inflammatory drugs), Interferons and Other Drugs. Based on the Distribution Channel, the market is segmented into Hospital Pharmacy, Online and Retail Pharmacies & Drug Stores. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis.
Scope of the Study
Market Segmentation:
By Indication
Approximately 50 million Americans suffer from autoimmune diseases, according to the National Institute of Health. The diseases are estimated to be one of the top 10 causes of death in females under the age of 65 and are the second largest cause of chronic disease. It is also the top cause of morbidity in females in the U.S. There are more than 80 clinically distinct types of autoimmune diseases recognized to date. Some of the prevalent kinds of autoimmune diseases are Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel illness, and due to the increasing autoimmune disease incidence, the demand for drugs used in autoimmune disease treatment is also increasing.
Based on Indication, the market is segmented into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications. Based on Drug Class, the market is segmented into Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs (Nonsteroidal anti-inflammatory drugs), Interferons and Other Drugs. Based on the Distribution Channel, the market is segmented into Hospital Pharmacy, Online and Retail Pharmacies & Drug Stores. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis.
Scope of the Study
Market Segmentation:
By Indication
- Rheumatic Disease
- Diabetes
- Multiple Sclerosis
- Inflammatory Bowel Disease
- Other Indications
- Anti-Inflammatory
- Anti-Hyperglycemics
- NSAIDs
- Interferons
- Other Drugs
- Hospital Pharmacy
- Online
- Retail Pharmacies and Drug Stores
- US
- Canada
- Mexico
- Rest of North America
- ABBOTT Laboratories
- Bio-Rad Laboratories, Inc.
- Johnson and Johnson
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Merck & Co., Inc.
- Bayer AG
- AbbVie, Inc.
- Amgen, Inc.
- Novartis AG
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Autoimmune Disease Therapeutics Market, by Indication
1.4.2 North America Autoimmune Disease Therapeutics Market, by Drug Class
1.4.3 North America Autoimmune Disease Therapeutics Market, by Distribution Channel
1.4.4 North America Autoimmune Disease Therapeutics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION
3.1 North America Rheumatic Disease Market by Country
3.2 North America Diabetes Market by Country
3.3 North America Multiple Sclerosis Market by Country
3.4 North America Inflammatory Bowel Disease Market by Country
3.5 North America Other Indications Market by Country
CHAPTER 4. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS
4.1 North America Anti-Inflammatory Market by Country
4.2 North America Anti-Hyperglycemics Market by Country
4.3 North America NSAIDs Market by Country
4.4 North America Interferons Market by Country
4.5 North America Other Drugs Market by Country
CHAPTER 5. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL
5.1 North America Hospital Pharmacy Market by Country
5.2 North America Online Market by Country
5.3 North America Retail Pharmacies and Drug Stores Market by Country
CHAPTER 6. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY
6.1 USA Autoimmune Disease Therapeutics Market
6.1.1 USA Autoimmune Disease Therapeutics Market by Indication
6.1.2 USA Autoimmune Disease Therapeutics Market by Drug Class
6.1.3 USA Autoimmune Disease Therapeutics Market by Distribution Channel
6.2 Canada Autoimmune Disease Therapeutics Market
6.2.1 Canada Autoimmune Disease Therapeutics Market by Indication
6.2.2 Canada Autoimmune Disease Therapeutics Market by Drug Class
6.2.3 Canada Autoimmune Disease Therapeutics Market by Distribution Channel
6.3 Mexico Autoimmune Disease Therapeutics Market
6.3.1 Mexico Autoimmune Disease Therapeutics Market by Indication
6.3.2 Mexico Autoimmune Disease Therapeutics Market by Drug Class
6.3.3 Mexico Autoimmune Disease Therapeutics Market by Distribution Channel
6.4 Rest of North America Autoimmune Disease Therapeutics Market
6.4.1 Rest of North America Autoimmune Disease Therapeutics Market by Indication
6.4.2 Rest of North America Autoimmune Disease Therapeutics Market by Drug Class
6.4.3 Rest of North America Autoimmune Disease Therapeutics Market by Distribution Channel
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Bio-Rad Laboratories, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 Johnson and Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Collaborations, partnerships and agreements:
7.4 GlaxoSmithKline PLC (GSK)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and mergers:
7.4.5.2 Collaborations, partnerships and agreements:
7.4.5.3 Product launches:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Approval:
7.6 Merck & Co., Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.7 Bayer AG (Bayer Schering Pharma AG)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Collaborations, partnerships and agreements:
7.8 AbbVie, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.9 Amgen, Inc.
7.9.1 Company overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Product launches:
7.9.5.2 Collaborations, partnerships and agreements:
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Acquisition and mergers:
7.10.5.2 Collaborations, partnerships and agreements:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Autoimmune Disease Therapeutics Market, by Indication
1.4.2 North America Autoimmune Disease Therapeutics Market, by Drug Class
1.4.3 North America Autoimmune Disease Therapeutics Market, by Distribution Channel
1.4.4 North America Autoimmune Disease Therapeutics Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION
3.1 North America Rheumatic Disease Market by Country
3.2 North America Diabetes Market by Country
3.3 North America Multiple Sclerosis Market by Country
3.4 North America Inflammatory Bowel Disease Market by Country
3.5 North America Other Indications Market by Country
CHAPTER 4. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS
4.1 North America Anti-Inflammatory Market by Country
4.2 North America Anti-Hyperglycemics Market by Country
4.3 North America NSAIDs Market by Country
4.4 North America Interferons Market by Country
4.5 North America Other Drugs Market by Country
CHAPTER 5. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL
5.1 North America Hospital Pharmacy Market by Country
5.2 North America Online Market by Country
5.3 North America Retail Pharmacies and Drug Stores Market by Country
CHAPTER 6. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY
6.1 USA Autoimmune Disease Therapeutics Market
6.1.1 USA Autoimmune Disease Therapeutics Market by Indication
6.1.2 USA Autoimmune Disease Therapeutics Market by Drug Class
6.1.3 USA Autoimmune Disease Therapeutics Market by Distribution Channel
6.2 Canada Autoimmune Disease Therapeutics Market
6.2.1 Canada Autoimmune Disease Therapeutics Market by Indication
6.2.2 Canada Autoimmune Disease Therapeutics Market by Drug Class
6.2.3 Canada Autoimmune Disease Therapeutics Market by Distribution Channel
6.3 Mexico Autoimmune Disease Therapeutics Market
6.3.1 Mexico Autoimmune Disease Therapeutics Market by Indication
6.3.2 Mexico Autoimmune Disease Therapeutics Market by Drug Class
6.3.3 Mexico Autoimmune Disease Therapeutics Market by Distribution Channel
6.4 Rest of North America Autoimmune Disease Therapeutics Market
6.4.1 Rest of North America Autoimmune Disease Therapeutics Market by Indication
6.4.2 Rest of North America Autoimmune Disease Therapeutics Market by Drug Class
6.4.3 Rest of North America Autoimmune Disease Therapeutics Market by Distribution Channel
CHAPTER 7. COMPANY PROFILES
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Bio-Rad Laboratories, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expenses
7.3 Johnson and Johnson
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Collaborations, partnerships and agreements:
7.4 GlaxoSmithKline PLC (GSK)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Acquisition and mergers:
7.4.5.2 Collaborations, partnerships and agreements:
7.4.5.3 Product launches:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Approval:
7.6 Merck & Co., Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.7 Bayer AG (Bayer Schering Pharma AG)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Collaborations, partnerships and agreements:
7.8 AbbVie, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.9 Amgen, Inc.
7.9.1 Company overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Product launches:
7.9.5.2 Collaborations, partnerships and agreements:
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Acquisition and mergers:
7.10.5.2 Collaborations, partnerships and agreements:
LIST OF TABLES
TABLE 1 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA RHEUMATIC DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA RHEUMATIC DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA DIABETES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA DIABETES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA OTHER INDICATIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA OTHER INDICATIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA NSAIDS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA NSAIDS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA INTERFERONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA INTERFERONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA OTHER DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA OTHER DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA HOSPITAL PHARMACY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA HOSPITAL PHARMACY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA ONLINE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA ONLINE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 40 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 41 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 42 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 43 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 44 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 45 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 48 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 49 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 50 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 51 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 52 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 53 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 56 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 57 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 58 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 59 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 60 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 61 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 63 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 64 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 65 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 66 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 67 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 68 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 69 KEY INFORMATION – BIO-RAD LABORATORIES, INC.
TABLE 70 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 71 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 72 KEY INFORMATION – PFIZER, INC.
TABLE 73 KEY INFORMATION – MERCK & CO., INC.
TABLE 74 KEY INFORMATION – BAYER AG
TABLE 75 KEY INFORMATION – ABBVIE, INC.
TABLE 76 KEY INFORMATION – AMGEN, INC.
TABLE 77 KEY INFORMATION – NOVARTIS AG
TABLE 1 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 2 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 3 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 4 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 5 NORTH AMERICA RHEUMATIC DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 NORTH AMERICA RHEUMATIC DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 NORTH AMERICA DIABETES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 NORTH AMERICA DIABETES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 NORTH AMERICA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 NORTH AMERICA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 NORTH AMERICA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 NORTH AMERICA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 NORTH AMERICA OTHER INDICATIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 NORTH AMERICA OTHER INDICATIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 16 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 17 NORTH AMERICA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 NORTH AMERICA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 NORTH AMERICA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 NORTH AMERICA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 NORTH AMERICA NSAIDS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 NORTH AMERICA NSAIDS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 NORTH AMERICA INTERFERONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 NORTH AMERICA INTERFERONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 NORTH AMERICA OTHER DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 NORTH AMERICA OTHER DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 28 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 29 NORTH AMERICA HOSPITAL PHARMACY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 NORTH AMERICA HOSPITAL PHARMACY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 NORTH AMERICA ONLINE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 NORTH AMERICA ONLINE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 NORTH AMERICA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 34 NORTH AMERICA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 35 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 38 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 39 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 40 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 41 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 42 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 43 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 44 USA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 45 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 46 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 47 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 48 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 49 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 50 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 51 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 52 CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 53 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 54 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
TABLE 55 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 56 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 57 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 58 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 59 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 60 MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 61 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
TABLE 62 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
TABLE 63 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
TABLE 64 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
TABLE 65 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
TABLE 66 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
TABLE 67 REST OF NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
TABLE 68 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 69 KEY INFORMATION – BIO-RAD LABORATORIES, INC.
TABLE 70 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 71 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 72 KEY INFORMATION – PFIZER, INC.
TABLE 73 KEY INFORMATION – MERCK & CO., INC.
TABLE 74 KEY INFORMATION – BAYER AG
TABLE 75 KEY INFORMATION – ABBVIE, INC.
TABLE 76 KEY INFORMATION – AMGEN, INC.
TABLE 77 KEY INFORMATION – NOVARTIS AG
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
